interleukin-12 + anti-NY-ESO-1 T cell receptor-transduced peripheral blood lymphocytes

This experimental adoptive cell therapy, developed by the National Cancer Institute (NCI), consists of autologous peripheral blood lymphocytes (PBLs) that have been retrovirally transduced to express both a high-affinity T-cell receptor (TCR) specific for the NY-ESO-1 cancer-testis antigen and the cytokine interleukin-12 (IL-12). The TCR is HLA-A*0201-restricted, allowing the engineered T cells to recognize and target NY-ESO-1-expressing metastatic cancer cells. The co-expression of IL-12 is intended to enhance the anti-tumor activity, persistence, and effector function of the T cells within the tumor microenvironment, potentially eliminating the need for systemic high-dose IL-2 administration. This investigational therapy was evaluated in a Phase I clinical trial (NCT01457131) for patients with metastatic cancers, including melanoma and renal cell carcinoma, but development was terminated due to significant toxicities observed during the study.

Other names

anti-ESO-1/IL-12 white blood cellsIL-12 and anti-NY-ESO-1 TCR gene-engineered lymphocytesIL12 and anti-NY-ESO-1 TCR gene-engineered lymphocytesIL 12 and anti-NY-ESO-1 TCR gene-engineered lymphocytesanti-NY-ESO-1 TCR-transduced T cells + IL-12